@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP1409090.RAsSSV2K5vKK4TFE9qqQ4IbKsbl2rpWiTTjPkKabnjueM130_head { this: np:hasAssertion dgn-np:NP1409090.RAsSSV2K5vKK4TFE9qqQ4IbKsbl2rpWiTTjPkKabnjueM130_assertion; np:hasProvenance dgn-np:NP1409090.RAsSSV2K5vKK4TFE9qqQ4IbKsbl2rpWiTTjPkKabnjueM130_provenance; np:hasPublicationInfo dgn-np:NP1409090.RAsSSV2K5vKK4TFE9qqQ4IbKsbl2rpWiTTjPkKabnjueM130_publicationInfo; a np:Nanopublication . dgn-np:NP1409090.RAsSSV2K5vKK4TFE9qqQ4IbKsbl2rpWiTTjPkKabnjueM130_assertion a np:Assertion . dgn-np:NP1409090.RAsSSV2K5vKK4TFE9qqQ4IbKsbl2rpWiTTjPkKabnjueM130_provenance a np:Provenance . dgn-np:NP1409090.RAsSSV2K5vKK4TFE9qqQ4IbKsbl2rpWiTTjPkKabnjueM130_publicationInfo a np:PublicationInfo . } dgn-np:NP1409090.RAsSSV2K5vKK4TFE9qqQ4IbKsbl2rpWiTTjPkKabnjueM130_assertion { miriam-gene:7157 a ncit:C16612 . lld:C0001418 a ncit:C7057 . dgn-gda:DGN5eb36531740a314bf58e68bc63173d60 sio:SIO_000628 miriam-gene:7157, lld:C0001418; a sio:SIO_001121 . } dgn-np:NP1409090.RAsSSV2K5vKK4TFE9qqQ4IbKsbl2rpWiTTjPkKabnjueM130_provenance { dgn-np:NP1409090.RAsSSV2K5vKK4TFE9qqQ4IbKsbl2rpWiTTjPkKabnjueM130_assertion dcterms:description "[In the clinical diagnostic arena: the World Health Organization established a standard nomenclature for intraductal papillary mucinous neoplasms, mucinous cystic tumors, intraductal mucinous hyperplasias, and solid pseudopapillary tumors; focal glandular differentiation may be commonly identified within pancreatic endocrine neoplasms (islet cell tumors) while not necessarily implying an unfavorable prognosis typical of ductal adenocarcinomas; positron emission tomography scanning may be used for evaluation of early tumor response to novel chemotherapeutic regimens; helical computed tomography (CT) is the state of the art in preoperative imaging for pancreatic cancer; neoadjuvant 5-fluorouracil (5-FU)-based chemoradiation in 39 resectable patients provided a median survival of 19 months, actuarial 4-year survival of 19%, and improved local tumor control; gemcitabine has shown promise in alleviating tumor-related symptoms with a significantly better clinical benefit response than single agent 5-FU (23.8 vs. 4.8%, p = 0.0022) based on change in pain intensity, daily analgesic consumption, performance status, and weight; a significant survival advantage was demonstrated in patients treated with conventional therapies whose tumors expressed p21WAF-1, an important inhibitor of cell cycle progression and downstream molecule of p53 and TGF-beta; a p21-adenovirus (rAD-p21) gene therapy resulted in significant growth inhibition of pancreatic cancer cell lines in tissue culture, and development of a successful SCID mouse-human pancreatic adenocarcinoma xenograft model provided an animal model for preclinical trials of rAD-p21.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_literature; sio:SIO_000772 miriam-pubmed:9821173; prov:wasDerivedFrom dgn-void:befree-2016; prov:wasGeneratedBy eco:ECO_0000203 . dgn-void:befree-2016 pav:importedOn "2016-02-19"^^xsd:date . dgn-void:source_evidence_literature a eco:ECO_0000212; rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en; rdfs:label "DisGeNET evidence - LITERATURE"@en . } dgn-np:NP1409090.RAsSSV2K5vKK4TFE9qqQ4IbKsbl2rpWiTTjPkKabnjueM130_publicationInfo { this: dcterms:created "2016-05-13T12:52:25+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetv3.0rdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v4.0.0.0" . dgn-void:disgenetv3.0rdf pav:version "v4.0.0" . }